Publications by authors named "Godfrey Musoro"

Claim this Profile
S
Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
Victor Musiime, Mutsa Bwakura-Dangarembizi, Alexander J Szubert, Vivian Mumbiro, Hilda A Mujuru, Godfrey Musoro

N Engl J Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Hylke Waalewijn, Man K Chan, Pauline D J Bollen, Hilda A Mujuru, Shafic Makumbi, Godfrey Musoro

Lancet HIV· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Anna Turkova, Ellen White, Hilda A Mujuru, Adeodata R Kekitiinwa, Cissy M Kityo, Godfrey Musoro

N Engl J Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status.
Sarah L Pett, Moira Spyer, Lewis J Haddow, Ruth Nhema, Laura A Benjamin, Godfrey Musoro

AIDS· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.
David Dunn, Huw Price, Tobias Vudriko, Cissy Kityo, Godfrey Musoro

J Acquir Immune Defic Syndr· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Pauline D J Bollen, Cecilia L Moore, Hilda A Mujuru, Shafic Makumbi, Adeodata R Kekitiinwa, Godfrey Musoro

Lancet HIV· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
Lisa L Ross, A Sarah Walker, Yu Lou, Allan R Tenorio, Diana M Gibb, Godfrey Musoro

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial.
Cissy Kityo, Alexander J Szubert, Abraham Siika, Robert Heyderman, Mutsa Bwakura-Dangarembizi, Godfrey Musoro

PLoS Med· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial.
Frank A Post, Alexander J Szubert, Andrew J Prendergast, Victoria Johnston, Hermione Lyall, Godfrey Musoro

Clin Infect Dis· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.
James Hakim, Victor Musiime, Alex J Szubert, Jane Mallewa, Abraham Siika, Godfrey Musoro

N Engl J Med· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial.
Alejandro Arenas-Pinto, Jennifer Thompson, Godfrey Musoro, Hellen Musana, Abbas Lugemwa

J Neurovirol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial.
Sylvia Kiwuwa-Muyingo, Bernard Kikaire, Ivan Mambule, Helen Musana, Godfrey Musoro

AIDS· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis